Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimerâ€™s disease psychosis, epilepsy, panic disorder and Parkinsonâ€™s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinsonâ€™s disease.

Employees

355

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Delayed Nasdaq Other stock markets 00:00:00 01/08/2024 +04			5-day change	1st Jan Change
44.96 ^USD	+0.74%		-.--%	-

05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Biotechnology Select Industry Index	CI
05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Global BMI Index	CI

Market Cap	8.19B 7.07B 6.5B 6.12B 11.49B 773B 11.59B 76.99B 29.98B 379B 30.74B 30.09B 1,313B	P/E 2022	-13.6x	P/E 2023	-15.9x
Enterprise Value	7.5B 6.47B 5.95B 5.6B 10.52B 707B 10.6B 70.46B 27.43B 347B 28.13B 27.53B 1,201B	EV / Sales 2022	-	EV / Sales 2023	-
Free-Float	93.64%	Yield 2022 *	-	Yield 2023	-

05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Biotechnology Select Industry Index	CI
05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Global BMI Index	CI
05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P TMI Index	CI
02/08/24	Analyst recommendations: Alphabet, Amazon, Lululemon, Intel, Qualcomm....
01/08/24	AbbVie Completes Acquisition of Cerevel Therapeutics	MT
01/08/24	AbbVie Completes Acquisition of Cerevel Therapeutics	MT
01/08/24	Cerevel Therapeutics Holdings, Inc. Announces Board Changes	CI
01/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from NASDAQ Composite Index	CI
01/08/24	AbbVie Inc. completed the acquisition of Cerevel Therapeutics Holdings, Inc. from FMR LLC and others.	CI
01/07/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Dynamic Index	CI
01/07/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell Midcap Growth Index	CI
01/07/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Index	CI
01/07/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from Russell 2000 Index	CI

02/08/24	Analyst recommendations: Alphabet, Amazon, Lululemon, Intel, Qualcomm....
15/02/24	Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	MT
28/12/23	JPMorgan Raises Price Target on Cerevel Therapeutics Holdings to $45 From $25, Keeps Neutral Rating	MT
22/12/23	Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40	MT
08/12/23	TD Cowen Downgrades Cerevel Therapeutics to Market Perform From Outperform, Price Target is $45	MT

Cerevel Therapeutics Holdings, Inc. Stock

Stocks

CERE

US15678U1280

Biotechnology & Medical Research

Valuation: Cerevel Therapeutics Holdings, Inc.

Latest news : Cerevel Therapeutics Holdings, Inc.

Analysts' recommendations: Cerevel Therapeutics Holdings, Inc.

Press Releases: Cerevel Therapeutics Holdings, Inc.

News in other languages: Cerevel Therapeutics Holdings, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cerevel Therapeutics Holdings, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

04/04/25	Entwistle & Cappucci LLP Files a Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc.	BU
01/04/25	Entwistle & Cappucci LLP is Investigating Potential Federal Securities Law Violations in Connection with Cerevel Therapeutics Holdings, Inc. (CERE)	BU
01/08/24	AbbVie Completes Acquisition of Cerevel Therapeutics	PR
19/04/24	Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease	AQ
18/04/24	Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease	AQ

02/08/24	RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Alphabet, Amazon, Lululemon, Intel, Qualcomm....
22/02/24	USA-Les valeurs à suivre à Wall Street (actualisé)
02/02/24	Omzetdaling Abbvie valt mee
13/12/23	Pharma und Gesundheit: weitere Konsolidierung
12/12/23	Farma en gezondheid: consolidatie gaat door

Manager	Title	Age	Since
Scott Reents PSD	President	59	01/08/2024
John Renger CTO	Chief Tech/Sci/R&D Officer	57	01/05/2019
Matthew Calistri IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Deborah Baron BRD	Director/Board Member	57	20/01/2021
Scott Reents BRD	Director/Board Member	59	01/08/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/08/24	Bain Capital Private Equity LP	Issuer sale	Company	65,679,781	36.0492%
01/08/24	Christopher Gordon	Issuer sale	Director	93,932	0.0516%
01/08/24	Bain Capital Private Equity LP	Issuer sale	Company	65,679,781	36.0492%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CEREVEL THERAPEUTICS HOLDINGS, INC.	+0.74%	-.--%	-.--%	+32.20%	8.19B
ARGENX SE	+3.23%	+2.25%	+65.02%	+116.66%	54.54B
WUXI APPTEC CO., LTD.	+0.04%	+5.05%	+43.44%	+36.75%	43.86B
BIONTECH SE	+2.96%	+6.91%	-12.26%	-16.23%	22.63B
INSMED INCORPORATED	+3.68%	+7.27%	-1.72%	+387.68%	20.7B
WUXI BIOLOGICS (CAYMAN) INC.	-0.53%	-0.27%	+12.68%	-37.07%	15.84B
GENMAB A/S	+5.27%	+1.87%	+13.67%	-38.00%	14.83B
EXELIXIS, INC.	+1.07%	+0.41%	+27.66%	+178.75%	13.1B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.17%	+4.13%	+13.12%	-	12.66B
MADRIGAL PHARMACEUTICALS, INC.	+0.98%	+7.15%	+80.62%	+105.73%	11.56B
Average	+1.22%	+0.16%	+24.22%	+85.16%	21.79B
Weighted average by Cap.	+1.63%	+0.17%	+32.13%	+89.21%

	2022	2023
Net sales	-	-
Net income	-352M -303M -279M -262M -493M -33.17B -497M -3.3B -1.29B -16.28B -1.32B -1.29B -56.32B	-433M -373M -343M -323M -607M -40.85B -612M -4.07B -1.58B -20.05B -1.62B -1.59B -69.35B
Net Debt	-523M -451M -415M -391M -734M -49.38B -740M -4.92B -1.91B -24.23B -1.96B -1.92B -83.84B	-695M -600M -552M -519M -976M -65.63B -984M -6.54B -2.54B -32.21B -2.61B -2.55B -111B

3 years	19.59	44.99
5 years	12.01	46.16
10 years	9	46.16